Skin lesions in sarcoidosis are often the initial symptoms that enable the dermatologist to be the first to diagnose this granulomatosis. However, diagnosis is sometimes very problematic. In 2015, the diagnostic criteria for sarcoidosis were updated in Japan, with elevated serum soluble interleukin-2 receptor (sIL-2R) replacing negative tuberculin reaction. Therefore, we assessed the clinical utility of sIL-2R compared with two other common markers, angiotensin-converting enzyme (ACE) and lysozyme, in patients who visited the dermatology clinic. Data from 72 patients showed that sIL-2R was more sensitive than both ACE and lysozyme in supporting a diagnosis of sarcoidosis (52.8%) compared with ACE (29%) and lysozyme (26.4%). Additionally, the sIL-2R level was significantly higher in patients with multiple organ involvement and parenchymal infiltration. Patients with elevated sIL-2R levels had higher serum ACE and lysozyme levels, a higher incidence of pulmonary involvement, more severe chest radiographic stage and a high incidence of expression-specific signs by imaging analysis. Receiver-operator curve analysis showed that sIL-2R was a better marker at the threshold cut-off point compared with ACE and lysozyme for identifying patients with multiple organ involvement, detecting patients with pulmonary disease and parenchymal infiltration as well as predicting the presence of specific signs in the diagnosis of sarcoidosis. Moreover, the kinetics of sIL-2R levels correlated closely with clinical manifestations, in contrast to the modest changes of ACE and lysozyme levels during the follow-up period. In conclusion, sIL-2R may be considered a good marker for diagnosis and a potential indicator of disease activity.
INTRODUCTION
Sarcoidosis is a systemic granulomatous disease of unknown cause, and its main feature is accumulation of activated T lymphocytes and mononuclear phagocytes, resulting in the formation of non-caseating granuloma. 1 Numerous organs maybe affected, but lungs, lymph nodes and skin are the most commonly involved. 2 Skin lesions present in 20-35% of all cases and are often the initial symptoms that enable the dermatologist to be the first to diagnose sarcoidosis. 3, 4 However, diagnosis is sometimes very problematic, because there is no definitive test, and it is only established by a combination of clinical manifestations, laboratory tests and imaging findings, as well as the presence of granuloma in biopsy tissue. Patients with initial sarcoidosis skin lesions often have systemic involvement at the time of diagnosis or a few years later. 5, 6 Therefore, dermatologists must be aware of extracutaneous involvement and must predict disease severity in routine clinical care. 4 Despite the widespread use of biomarkers in clinical practice, sufficient data have not been available regarding which biomarkers are suitable for diagnosis, evaluation of activity and prediction of treatment response in sarcoidosis. Soluble interleukin-2 receptor (sIL-2R) is a 55-kDa protein released mainly by activated T lymphocytes; therefore, levels of sIL-2R have been considered to be a marker of T-cell activation. 7, 8 In sarcoidosis, increased levels of sIL-2R in serum and bronchoalveolar lavage fluid (BALF) have been reported, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] and serum levels of sIL-2R were correlated with various indices of disease severity, including angiotensin-converting enzyme (ACE), radiographic stage of disease, gallium-67 ( Based on these observations, the diagnostic criteria for sarcoidosis were updated in Japan in 2015, with elevated serum sIL-2R replacing negative tuberculin reaction. 26 To the best of our knowledge, however, a study of serum sIL-2R levels in sarcoidosis has not been conducted in the dermatology field. The aim of this study was to assess the clinical utility of serum sIL-2R from a dermatological point of view, compared with ACE and lysozyme for diagnosis, severity assessment and follow up.
METHODS

Study participants
We collected information regarding sarcoidosis retrospectively from patient clinical charts. The study group consisted of 72 patients (11 men and 61 women) who were admitted to the Dermatology Department of Kansai Medical University Hospital (Osaka, Japan) from December 2008 to October 2016 and who had available sIL-2R test results. The patients with autoimmune or inflammatory diseases, transplantation or rejection, hematological malignancies, renal failure and infectious disorders were excluded from this study because elevated sIL-2R levels have been reported in these conditions. 27 None of the patients received the systemic treatment within 1 month before their first visit. The study protocol was approved by the internal review board of Kansai Medical University (H150392).
Complete medical histories, clinical examinations and laboratory tests were conducted for all patients at the first visit, at which evaluation focused particularly on extracutaneous involvement (skin, lung, heart, eye, muscle, joint, pancreas, spleen, liver), as described previously. [28] [29] [30] Skin lesions were assessed by biopsy; chest radiogram and high-resolution computed tomography (CT) were used to assess pulmonary involvement, including bilateral hilar lymphadenopathy (BHL), parenchymal infiltrates or pulmonary fibrosis; and eye involvement, including uveitis, was evaluated by split-lamp and fundoscopic examination. The panda sign, the lambda sign as well as other involved organs were examined by imaging with 18 Ffluorodeoxyglucose positron emission tomography (FDG PET) and/or 67 Ga scintigraphy uptake. Patient characteristics are summarized in Table 1 .
Laboratory analyses
Blood samples from 72 patients were collected for assay of sIL-2R, and paired with routine analyses at the first visit. Follow-up sIL-2R tests were obtained in 44 patients at least twice. The levels of sIL-2R were assessed at LSI Medience (Tokyo, Japan) with a commercially available enzyme-linked immunosorbent assay, and its normal range was 124-466 U/mL. ACE, lysozyme, KL-6, C-reactive protein (CRP), white blood cell count (WBC), and the percentage of peripheral monocytes and eosinophils in WBC were measured using standard methods in the clinical laboratory (normal values: ACE, 6.6-21.4 U/L; lysozyme, 5-10.2 lg/mL; KL-6, 0-500 U/mL; CRP, 0-0.3 mg/dL; WBC count, 3500-8500/lL; peripheral monocytes, 3-9%; eosinophils, 0.5-6%).
Statistical analysis
All values with normal distributions are shown as mean (standard deviation), while those with non-normal distributions are expressed as median (range), for which range is the 25-75th percentile. The Mann-Whitney U-test, Student's t-test and one-way ANOVA test were used to compare means of different groups. A post-hoc test (Tukey's test) was used following the ANOVA test in case the difference between groups was statistically significant. Analysis of nominal values was conducted with the v 2 -test and McNemar's test. Spearman's and Pearson's correlation coefficients were used to correlate any two variables with non-normal and normal distribution, respectively. In order to evaluate the performance of serum sIL-2R, ACE and lysozyme for the diagnosis of number of involved organs, presence of specifics signs (BHL and/or the lambda sign and/ or the panda sign), parenchymal infiltration, pulmonary involvement, eye lesions and extracutaneous manifestations, the sensitivity, specificity and area under the curve (AUC) were calculated with a receiver-operator curve (ROC) analysis. P < 0.05 was considered statistically significant. Statistical analyses were carried out and graphical representations were constructed with SPSS statistics (version 20; IBM, Armonk, NY, USA).
RESULTS
Serum sIL-2R levels in sarcoidosis
The serum sIL-2R concentrations of 72 patients with sarcoidosis were measured, and the median level was 497 U/mL (range, 354.6-847.5). This represented an increase compared with the normal range (124-466 U/mL) (Fig. 1) . 
Sensitivity of sIL-2R increases compared with ACE and lysozyme
Angiotensin-converting enzyme and lysozyme have been used in the diagnosis of sarcoidosis and in the evaluation of disease activity. 4, 14, 15, [30] [31] [32] [33] [34] When compared with these traditional markers, increased serum sIL-2R levels were found in 52.8% of patients, while elevated ACE was found in only 29% of patients, and high lysozyme levels were found in only 26.4%. These differences were statistically significant (P = 0.001 for sIL-2R vs ACE and P < 0.05 for sIL-2R vs lysozyme) ( Table 2) . In this study, serum sIL-2R and ACE levels were measured simultaneously in 69 patients with sarcoidosis. Twenty-one of 69 patients (30.4%) had elevated levels of serum sIL-2R at the first examination without any increase in serum ACE, while only four of 69 patients (5.8%) had normal sIL-2R levels with increased ACE levels (Table 2a) . We also evaluated serum sIL-2R and lysozyme levels at the same time in 53 patients. Elevated sIL-2R levels with normal levels of lysozyme were found in 10 of the 53 (18.9%) patients, while only two (3.8%) had elevated lysozyme levels and normal levels of sIL-2R (Table 2b) .
Sera were obtained for the measurement of all three markers at the first visit in a total of 50 patients. The correlation between sIL-2R levels and others factors is shown in Table 3 . Serum sIL-2R levels were significantly correlated with serum ACE and lysozyme levels (P < 0.001 and < 0.001, respectively), WBC count (P < 0.005), the percentage of peripheral eosinophils (P < 0.005) and CRP (P < 0.005) (Fig. 2) . No significant correlations between serum sIL-2R levels and age, duration of disease, percentage of peripheral monocytes and serum KL-6 levels were observed.
Serum sIL-2R levels and involvement of other organs
Pulmonary involvement was evaluated in a total of 63 patients. After six patients with undetermined lesions related to sarcoidosis were excluded, there were 18 patients with stage I pulmonary disease and eight patients with stage II pulmonary disease. There was a significant increase in serum sIL-2R levels in patients with stage II pulmonary disease compared with patients with normal pulmonary function and patients with stage I pulmonary disease (P < 0.001, Fig. 3a ).
Disease extent and severity are best judged by the number of involved organs and organs with impaired function. 30 The number of affected organs was evaluated with FDG PET and/ or 67 Ga scintigraphy uptake. Elevated serum sIL-2R levels were significantly associated with the number of involved organs in sarcoidosis (P < 0.01). Patients with more than three involved organs had significantly higher sIL-2R levels in comparison with those with three or fewer involved organs (P < 0.01, Fig. 3b ).
Characteristics of patients with elevated and normal sIL-2R levels
Skin lesions in sarcoidosis can be divided into acute lesions and chronic lesions in which systemic involvement is related to acute lesions. 2, 3 Interestingly, these acute skin lesions, including papular and macular lesions, were found more frequently in patients with high sIL-2R than without, although the difference was not significant. Erythema nodosum, a non-specific acute lesion, was found on both legs of a female patient as well as in a scar sarcoid lesion on her right knee; her sIL-2R level was normal, and no evidence of systemic involvement was seen by 67 Ga scintigraphy uptake. In contrast, chronic lesions, including scars and lichenoid lesions, were significantly more common in patients without elevated serum sIL-2R levels (P < 0.05 and < 0.05, respectively) ( Table 4) .
We compared the clinical and laboratory findings between patients with elevated serum sIL-2R levels and those with normal values. Patients with increased levels of sIL-2R had a significantly higher frequency of multiple areas of skin involvement (P < 0.05), pulmonary involvement (P < 0.001), severity of chest radiographic staging (P < 0.01), presence of specific signs (lambda sign and/or panda sign and/or BHL), (P < 0.01) and higher levels of CRP (P < 0.01), ACE (P < 0.001) and lysozyme (P < 0.001) ( Table 4) . Because the sIL-2R level is considered to be a marker of extrapulmonary disease in sarcoidosis, 9 we also compared the frequency of eye, liver, spleen, heart, pancreas and joint involvement in patients with and without elevated sIL-2R levels.
Patients with elevated serum sIL-2R levels had a tendency toward a higher frequency of extrapulmonary disease, although significant differences were not observed in our study. There were no significant differences between groups in age, sex, duration of disease, frequency of extracutaneous involvement and treatment (Table 4 ). (a) sIL-2R levels in patients with stage II pulmonary involvement were significantly higher than those in patients with stage 0 and stage I pulmonary involvement (Tukey's test, **P < 0.01 and **P < 0.01, respectively). (b) sIL-2R levels were highest in patients with more than three involved organs. The difference was statistically significant between this group and patients with three or fewer involved organs (Tukey's test, **P < 0.01 and **P < 0.01, respectively). The horizontal bars show the median values. sIL-2R, soluble interleukin-2 receptor.
Diagnostic performance of sIL-2R
As levels of ACE and lysozyme have been used in the management of disease, 32 we next analyzed the value of sIL-2R levels for assessing the severity of sarcoidosis in comparison with these inflammatory markers. ROC analysis was used to compare these parameters for the number of involved organs, presence of specific signs (BHL and/or lambda sign and/or panda sign), eye involvement, parenchymal infiltration, pulmonary disease and extracutaneous involvement (Fig. 4 , Table 5 ).
For prediction of disease extent in more than three organs, the AUC of sIL-2R was 0.889 with a 95% confidence interval (CI) of 0.793-0.985; in comparison, with ACE, it was 0.784 (95% CI, 0.646-0.922) and with lysozyme, it was 0.680 (95% CI, 0.380-0.980) (Fig. 4a) . The best discriminatory value of sIL-2R was obtained at a cut-off point of 634 U/mL with a corresponding sensitivity and specificity of 100% and 77.8%, respectively. This optimal cut-off point was approximately 1.3-times higher than the upper limit of the laboratory normal value. For the standard threshold, the sensitivity was maintained at 100%, but the specificity dropped to 60%.
For prediction of specific signs of sarcoidosis, including BHL, the lambda sign and the panda sign, the AUC of sIL-2R was 0.805 (95% CI, 0.675-0.935), with a corresponding sensitivity and specificity of 80% and 62.1%, respectively, which was higher in comparison with ACE (0.790 with 95% CI of Except where indicated otherwise, values are median (range) with range is 25-75th percentiles. *P < 0.05, **P < 0.01, ***P < 0.001 by Mann-Whitney U-test and v 2 -test. ACE, angiotensin-converting enzyme; BHL, bilateral hilar lymphadenopathy; CRP, C-reactive protein; SD, standard deviation; sIL-2R, soluble interleukin-2 receptor; WBC, white blood cells. 0.650-0.929) and lysozyme (0.680 with 95% CI of 0.504-0.857). Both sIL-2R and ACE, but not lysozyme, may be useful markers to predict the presence of these specific signs by imaging analysis for sarcoidosis (Fig. 4b) .
For assessing the severity of pulmonary involvement, all of the markers may be used to identify parenchymal infiltration (≥ stage II) at the standard threshold, with AUC values of sIL-2R, ACE and lysozyme of 0.797, 0.806 and 0.806, respectively. The serum sIL-2R level at the cut-off point was 466.5 U/mL, with a corresponding sensitivity and specificity of 71.4% and 48.4%, respectively (Fig. 4c) .
In order to discriminate sarcoidosis patients with and without pulmonary involvement, the AUC of sIL-2R, ACE and lysozyme were evaluated and determined to be 0.826, 0.829 and 0.706, respectively. At the standard threshold, sIL-2R was more sensitive than ACE or lysozyme (80% compared with 46.7% for ACE and 53.3% for lysozyme), but less specific (65.2% compared with 87% for ACE and 82.6% for lysozyme) (Fig. 4d) .
After ROC analysis, neither sIL-2R, ACE nor lysozyme had a sufficient AUC at the standard threshold to have adequate power for detection of eye involvement or extracutaneous involvement in our patients (Table 5) .
Changes in serum sIL-2R levels during the follow-up period
Forty-four patients were tested for sIL-2R at least twice during their medical care at our hospital. Of those patients, only 24 had an increased sIL-2R level at least once during the followup period. Changes in sIL-2R levels in 20 of 22 patients (90.1%) were found to correlate with clinical progress (characteristics of lesions, chest radiographic stage or change in imaging tests). In particular, we noticed that there were 11 cases (50%) with elevated sIL-2R levels but values of ACE and lysozyme in the normal range. Another six cases that had high levels of sIL-2R and ACE concentrations had slightly increased levels during follow up.
We show two representative cases in Figure 5 . Case 1 was a 77-year-old female patient with multiple annular lesions on her face, abdomen, arms and legs. She also had uveitis and many mediastinal lymph nodes on 67 Ga scintigraphy uptake. On her first visit, the sIL-2R level was high, at 672 U/mL, Figure 4 . ROC plots express the diagnostic performance of sIL-2R compared with ACE and lysozyme. ROC curve to predict patients with (a) more than three involved organs, (b) BHL and/or lambda sign, (c) parenchymal infiltration, (d) pulmonary involvement. The diagonal line indicates an AUC of 0.5 (no discrimination between two states). ACE, angiotensin-converting enzyme; AUC, area under the curve; BHL, bilateral hilar lymphadenopathy; ROC, receiver-operator curve; sIL-2R, soluble interleukin-2 receptor.
while others markers were normal (ACE, 15.1 UI/L; lysozyme, 6.3 lg/mL). She started systemic corticosteroid treatment because her lesions became more generalized despite treatment with topical corticosteroids and oral doxycycline. Her sIL-2R level gradually decreased during the treatment. After 16 months, her skin lesions achieved good response and sIL-2R level returned to the normal range (Fig. 5a) .
The second case was a 72-year-old female patient with multiple areas of skin lesions on her face, arms and knees (papules, macules, scars, subcutaneous nodules). She had uveitis with BHL found on chest radiography. FDG PET showed high metabolic activity in the hilar and mediastinal lymph nodes and in the pancreas. ACE levels measured at the same time as sIL-2R levels were always in the normal range, while lysozyme was slightly elevated. When the sIL-2R level reached 4750 U/mL, some new subcutaneous nodules appeared on her arms. She was treated with topical corticosteroids and immunomodulatory drugs under careful follow up. Her skin lesions have improved with decreasing sIL-2R levels (Fig. 5b) .
DISCUSSION
In line with previous works, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] 35 we found that serum sIL-2R levels were significantly higher than normal in patients with sarcoidosis (Fig. 1) . The sensitivity of ACE levels in the diagnosis of sarcoidosis was reported at approximately 40-60% depending on the study. 31, 32, 34, 36 In our study, however, the ACE level was lower, at 29%, which is similar to a previous study. 32 In addition, 69% of patients with sarcoidosis were reported to have a high level of serum lysozyme but the sensitivity of lysozyme was just 26% in our study. 32 In contrast to ACE and lysozyme, elevated serum sIL-2R levels were found in 52.8% of patients and were significantly more valuable than ACE and lysozyme (P < 0.001 and < 0.05, respectively). Therefore, the level of sIL-2R in sera may be a better parameter to support a diagnosis of sarcoidosis compared with ACE or lysozyme, even in patients who visited a dermatology clinic. Serum sIL-2R levels were also correlated with levels of ACE and lysozyme, two markers used in monitoring the activity of the disease. 33 ,34 ACE and lysozyme levels were shown as quite helpful in monitoring sarcoidosis activity in a previous study, but another study showed that they were less useful. 31,32 The serum sIL-2R level was reported to be a good marker of activity. 12, [16] [17] [18] [19] 21, 22, 35 Acute skin lesions were found more frequently in patients with elevated sIL-2R levels, even though the possible source of sIL-2R was not restricted to the skin tissue, indicating that it was possibly related to the acute activity of sarcoidosis. Conversely, chronic lesions, including scars and lichenoid lesions, were found more frequently in patients without increased sIL-2R levels (Table 4) . Serum sIL-2R also remains a good index for assessing pulmonary stage and functional impairment, but ACE and lysozyme do not. 11, 14, 20, 25 Consistent with these previous reports, serum sIL-2R in our study was correlated with different pulmonary stages, in which sIL-2R was highest in patients with stage II compared with stage 0 and stage I pulmonary disease (P < 0.01) (Fig. 3a) . By screening with FDG PET and/or 67 Ga scintigraphy uptake, the number of involved organs was counted and a significant correlation was found with sIL-2R levels. Patients with more than three involved organs had a significantly higher value of sIL-2R than patients with three or fewer involved organs (Fig. 3b) . This observation could be explained by association of sIL-2R, a marker of T-cell activation, with the total granular burden in sarcoidosis. Moreover, according to previous reports, sIL-2R is also secreted by monocytes, B cells and AUC of markers compared with true area = 0.5; *P < 0.05, **P ≤ 0.01, ***P ≤ 0.001. ACE, angiotensin-converting enzyme; AUC, area under the curve; BHL, bilateral hilar lymphadenopathy; CI, confidence interval; sIL-2R, soluble interleukin-2 receptor.
alveolar macrophages in sarcoidosis. 19 Thus, serum sIL-2R levels may be a good marker to reflect the systemic inflammatory condition of sarcoidosis, and we recommend that clinical physicians should be aware of any patient with a high sIL-2R level, because the patient may have multi-organ involvement. A previous report showed increased percentages of neutrophils (> 3.0%) and eosinophils (> 1%) in BALF from patients with progressive disease, and these findings reflected an ongoing inflammatory reaction. 17 Here, in this study, we present data demonstrating that serum sIL-2R levels were also significantly correlated with the WBC count (P < 0.005) and the percentage of peripheral eosinophils (P < 0.005). Further research to elucidate the precise role of these cells in the pathogenesis of sarcoidosis is needed. CRP levels were significantly higher in patients with increased sIL-2R levels. This point was also in accordance with an observation in a previous study that indicated an increased CRP level associated with the acute phase response. 17, 37 Clinical and laboratory observations in patients with elevated serum sIL-2R levels compared with those without showed a higher incidence of multiple areas of skin lesions, pulmonary involvement, severe radiology stages, presence of specifics signs (BHL and/or lambda sign and/or panda sign), and higher levels of CRP, ACE and lysozyme (Table 4 ). In contrast to previous studies, 15 associations between sIL-2R and eye involvement and extracutaneous involvement were not established. Angiotensin-converting enzyme is produced by T-cell-stimulated endothelial cells at the periphery of the granuloma. Thus, ACE may reflect more directly the granuloma formation in sarcoidosis. 3 Compared with ACE and lysozyme, however, serum sIL-2R was a good index of disease extent, with a sensitivity of 100% and a specificity of 60% at the standard threshold. Serum sIL-2R levels were also shown to be a sensitive parameter associated with pulmonary lesions and presence of specific signs (BHL, lambda sign, panda sign) in comparison with ACE and lysozyme (sensitivity of~80%). Because sIL-2R is an indicator of T-cell activation, 30 it is reasonable to assume that activated lymphocytes, together with other IL-2R-expressing cells, 19 retain important roles in the pathogenesis of sarcoidosis. Serial serum sIL-2R levels were measured and, in 20 patients with increased sIL-2R, these values were correlated with clinical progress. A similar observation was obtained in a previous report suggesting a predictive value of serum sIL-2R measurement for monitoring disease activity and follow up. 11, 18, 38 In contrast, in this study, ACE and lysozyme seemed not helpful during follow up, in line with previous works. 14, 17 As the ACE level has been influenced by polymorphisms of ACE genes and can be depressed by systemic corticosteroid therapy, 39, 40 we recommend that the serial measurement of serum sIL-2R, a convenient non-invasive test, should be conducted as a support parameter for monitoring the activity of disease. Based on the data reported herein, a higher level of sIL-2R is linked to pulmonary lesions and may help to predict which patients will have multiple organ involvement in sarcoidosis. In comparison with ACE and lysozyme levels, sIL-2R level may be a more sensitive marker to support a diagnosis of sarcoidosis and may be helpful in evaluation of disease activity. Figure 5 . Changes in serum sIL-2R levels during the course of two representative cases with sarcoidosis. (a) A 77-year-old female patient with many areas of annular erythema on her face, abdomen, arms and legs. Eye involvement included uveitis. There were many mediastinal lymph nodes showing on gallium-67 scintigraphy uptake. Note that the sIL-2R (U/mL) level was high, at 672 U/ mL, while the ACE (U/L) and lysozyme (lg/mL) levels were normal. sIL-2R levels gradually decreased during the treatment, and her skin lesions had improved after 16 months of therapy. (b) A 72-year-old female patient with many papules, macules, scars, subcutaneous nodules on the face, arms and knees. She also had uveitis. 18 F-fluorodeoxyglucose positron emission tomography showed BHL, many mediastinal lymph nodes and an involved pancreas. The sIL-2R level was always high, while the level of ACE was normal and the level of lysozyme was slightly increased. Some new subcutaneous nodules appeared on her arms when the sIL-2R level reached 4750 U/mL. She was treated with topical corticosteroids with careful follow up. The red horizontal line shows the threshold sIL-2R level at 466 U/mL. ACE, angiotensin-converting enzyme; BHL, bilateral hilar lymphadenopathy; sIL-2R, soluble interleukin-2 receptor.
